USE OF BUSPIRONE FOR TREATMENT OF CEREBELLAR-ATAXIA - AN OPEN-LABEL STUDY
USE OF BUSPIRONE FOR TREATMENT OF CEREBELLAR-ATAXIA - AN OPEN-LABEL STUDY
复制标题
DOI：
10.1001/archneur.1995.00540340074015
复制
发表时间：
1995-10-01
影响因子：
--
通讯作者：
HALLETT, M
中科院分区：
文献类型：
--
作者：
LOU, JS;GOLDFARB, L;HALLETT, M
目的：评价5-羟色胺（1A）激动剂盐酸丁螺环酮治疗小脑性共济失调的疗效。设计：开放标签研究，20例患者（14例小脑皮质萎缩，6例橄榄空脑小脑萎缩）接受盐酸丁螺环酮治疗，剂量为60mg /d，持续8周。单位：研究医院。主要观察指标：临床、生理和心理评估。结果：完成研究的9例轻度或中度小脑功能障碍患者在临床和自我评估评分上有显著改善，但在运动表现测试、姿势摄影（数据不完整）、状态-特质焦虑量表和贝克抑郁量表上没有明显改善。完成研究的7名严重小脑功能障碍患者在任何指标上都没有改善。结论：丁螺环酮可有效治疗轻中度小脑性共济失调。对丁螺环酮治疗小脑共济失调的疗效进行双盲研究是必要的。
Objective: To evaluate the efficacy of buspirone hydrochloride, a serotonin (5-hydroxytryptamine(1A)) agonist, in treating patients with cerebellar ataxia.Design: Open-label study in which 20 patients (14 with cerebellar cortical atrophy and six with olivopontocerebellar atrophy) received buspirone hydrochloride, up to 60 mg/d, for 8 weeks.Setting: Research hospital.Main Outcome Measures: Clinical, physiological, and psychological assessment.Results: Nine patients with mild or moderate cerebellar dysfunction who completed the study showed significant improvement in clinical and self-assessment ratings, but not in a motor performance test, posturography (data were incomplete), State-Trait Anxiety Inventory, and Beck Depression Inventory. Seven patients with severe cerebellar dysfunction who completed the study had no improvement on any measure.Conclusions: Buspirone may be effective in treating mild to moderate cerebellar ataxia. A double-blind study of the efficacy of buspirone in cerebellar ataxia is warranted.